Carteolol ophthalmic Pregnancy and Breastfeeding Warnings
Brand names: Ocupress
Medically reviewed by Drugs.com. Last updated on Aug 3, 2023.
Carteolol ophthalmic Pregnancy Warnings
This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.
US FDA pregnancy category: C
Comments:
-A risk for intra uterine growth retardation has been shown when beta-blockers are administered orally.
-Signs and symptoms of beta blockade (e.g., bradycardia, hypotension, respiratory distress and hypoglycemia) have been reported in neonates when beta-blockers have been administered until delivery.
-Neonates should be monitored during the first days of life.
Animal studies have revealed increased resorptions and decreased fetal weights. There are no adequate and well-controlled studies in pregnant women.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Carteolol ophthalmic Breastfeeding Warnings
Caution is recommended.
Excreted into human milk: Unknown
Excreted into animal milk: Yes
Comments: The effects in the nursing infant are unknown.
See also
References for pregnancy information
- Product Information. Ocupress (carteolol ophthalmic). Ciba Vision Ophthalmics. 2001;PROD.
- Cerner Multum, Inc. UK Summary of Product Characteristics.
References for breastfeeding information
- Product Information. Ocupress (carteolol ophthalmic). Ciba Vision Ophthalmics. 2001;PROD.
- Cerner Multum, Inc. UK Summary of Product Characteristics.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
